A multidisciplinary approach to assess erectile dysfunction in high-risk cardiovascular patients

International Journal of Impotence Research

Volumn 17, Issue SUPPL. S1, 2005, Pages

  Schwarz, E R ^a,b   Rastogi, S ^a   Rodriguez, J J ^a   Kapur, V ^a   Sulemanjee, N ^a   Gupta, R ^a   Rosanio, S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Cardiac disease; Erectile dysfunction; Phosphodiesterase inhibitors

Indexed keywords

ANDROGEN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOMORPHINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; LOSARTAN; METOPROLOL; MOLSIDOMINE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V INHIBITOR; PROPRANOLOL; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; THIAZIDE DIURETIC AGENT; VALSARTAN; VARDENAFIL; YOHIMBINE;

ANDROGEN THERAPY; ANTICOAGULANT THERAPY; ARTERIAL INSUFFICIENCY; BLEEDING; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; ERECTILE DYSFUNCTION; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFECTION; META ANALYSIS; NONHUMAN; PATIENT EDUCATION; PENIS PROSTHESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHESIS FAILURE; REVIEW; RISK FACTOR; SEXUAL FUNCTION; SEXUALITY; SURGICAL RISK; SYNCOPE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT CONTRAINDICATION; VACUUM;

ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; RISK FACTORS; SEXUAL BEHAVIOR;

EID: 30044451652     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901427     Document Type: Review

References (52)

1. Kaiser FE et al. Impotence and aging: clinical and hormonal factors. J Amer Geriatr Soc 1988; 36: 511-519.
2. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 2341-2345.
3. Shabsigh R, Fishman IJ, Schum C, Dunn JK. Cigarette smoking and other vascular risk factors in vasculogenic impotence. Urology 1991; 38: 227-232.
4. Derby CA et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 302-306.
5. Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 2003; 91: 230-231.
6. Montorsi F et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360-365.
7. Kloner R et al. Erectile dysfunction in the cardiac patient: how common and how should we treat? J Urol 2003; 170: S46-S50.
8. Greenstein A et al. Does severity of ischemic coronary disease correlate with erectile dysfunction? Int J Impot Res 1997; 9: 123-126.
9. Pritzker MR. The penile stress test: A window to the hearts of man? Circulation 1999; 100(Suppl 1): 1-711.
10. Solomon H et al. Erectile dysfunction: Cardiovascular risk and the role of cardiologist. Int J Clin Pract 2003; 57: 96-99.
11. Ludmer P et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Eng J Med 1986; 315: 1046-1051.
12. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changing blood flow: An endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol 1990; 16: 349-356.
13. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1: 181-184.
14. Drexler H et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69: 1596-1601.
15. Elsner D, Muntze A, Kromer EP, Riegger GA. Systemic vasoconstriction induced by inhibition of nitric oxide synthesis is attenuated in conscious dogs with heart failure. Cardiovasc Res 1991; 25: 438-440.
16. Kubo SH et al. Lack of contribution of nitric oxide of basal vasomotor tone in heart failure. Am J Cardiol 1994; 74: 1133-1136.
17. Stewart DJ, Pohl U, Bassange E. Free radicals inhibits endothelium-dependent dilation in the coronary resistance bed. Am J Physiol 1988; 255: H765-H769.
18. Boger RH, Bode-Boger SM, Frolisch JC. The L- arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis 1996; 127: 1-11.
19. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 2005; 65: 773-786.
20. Grimm HR, Grandits GA, Svendsen K, TOMHS Research Group. Incidence and disappearance of erectile problems in men treated with for stage I hypertension: the treatment of mild hypertension study (TOMHS). Eur Urol 1996; 30(Suppl 2): 26.
21. Silvestri A et al. Report of erectile dysfunction after therapy with beta blockers is related to patient knowledge of the side effects and is reversed by placebo. Eur Heart J 2003; 24: 1928-1932.
22. Croog SH, Levine S, Testa MA, Sudilovsky A. The effects on antihypertensive therapy on quality of life. New Engl J Med 1986; 314: 1657-1664.
23. Piha J, Kaaja R. Effects of monoxidine and metoprolol in penile circulation in hypertensive men with erectile dysfunction: results of a pilot study. Int J Impot Res 2003; 5: 287-289.
24. Ko DT et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351-357.
25. Buffum J. Pharmosexology update: prescription drugs and sexual function. J Psychoactive Drugs 1986; 18: 97-106.
26. DiBianco R. A large-scale trial of captopril for mild to moderate heart failure in the primary care setting. Clin Cardiol 1991; 14: 676-682.
27. Yamamoto S et al. The effects of replacing dihydropyridine calcium-channel blockers with angiotensin II receptor blocker on the quality of life in hypertensive patients. Blood Pressure 2003; 12: 22-28.
28. Llisterri JL et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336-341.
29. Fogari R et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27-31.
30. Stern ME, Pascale L, Ackerman A. Life adjustment postmyocardial infarction. Arch Intern Med 1977; 137: 1680-1684.
31. Johnston BL, Cantwell JD, Watt EW, Fletcher GF. Sexual activity in exercising patients after myocardial infarction and revascularization. Heart Lung 1978; 7: 1026-1031.
32. Bloch A, Maeder J, Haisley J. Sexual problems after myocardial infarction. Am Heart J 1975; 90: 536-537.
33. Papadapoulos C, Beaumon C, Helley SI, Larrimore P. Myocardial infarction and sexual activity of the female patient. Arch Intern Med 1983; 143: 1528-1530.
34. Papadopoulos C et al. Sexual activity after coronary bypass. Chest 1986; 90: 681-685.
35. Feldman HA et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
36. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-261.
37. Fink HA et al. Sildenafil for male erectile dysfunction. A systematic review and meta-analysis. Arch Intern Med 2002; 162: 1349-1360.
38. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-1414.
39. Porst H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192-199.
40. Porst H, Padma-Nathan H, Giuliano F, Anglin G. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121-125.
41. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110: 3149-3155.
42. Dula E, Bukofzer S, Perdok R, George M, For the Apomorphine SL Study Group. Double-blind, crossover comparison on 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558-563.
43. Guay AT et al. Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial. Int J Impot Res 2002; 14: 25-31.
44. Morgentaler A. Male impotence. Lancet 1999; 354: 1713-1718.
45. Wang C et al. Longterm testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085-2098.
46. Virag R et al. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8 year experience with 615 cases. J Urol 1991; 145: 287-292.
47. Vaidyanathan S, Krishnan KR. Myocardial infarction associated with intra-cavernosal administration of alprostadil in a patient with spinal cord injury and paraplegia. Spinal Cord 1996; 34: 754-755.
48. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil - a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997; 9: 187-192.
49. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol 1997; 15: 78-82.
50. Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of and patient satisfaction with the ambicor inflatable penile prosthesis: results of a 2 center study. J Urol 2001; 166: 932-937.
51. Carson CC, Mulcahy JJ, Govier FE, the AMS 700CX study group. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a longterm multicenter study. J Urol 2000; 164: 376-380.
52. Solomon H, Man J, Martin E, Jackson G. Role of exercise treadmill testing in the management of erectile dysfunction: a joint cardiovascular/erectile dysfunction clinic. Heart 2003; 89: 671-672.